CA2352405A1 - New diphenylurea derivatives, their preparation process and the pharmaceutical compounds that contain them - Google Patents
New diphenylurea derivatives, their preparation process and the pharmaceutical compounds that contain them Download PDFInfo
- Publication number
- CA2352405A1 CA2352405A1 CA002352405A CA2352405A CA2352405A1 CA 2352405 A1 CA2352405 A1 CA 2352405A1 CA 002352405 A CA002352405 A CA 002352405A CA 2352405 A CA2352405 A CA 2352405A CA 2352405 A1 CA2352405 A1 CA 2352405A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- hydrogen
- cyano
- nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
L'invention concerne de nouveaux composés répondant à la formule (I) : (voir formule I) dans laquelle R1, R2, R3 et R4 représentent indépendamment un atome d'hydrogène, ou d'halogène, ou un groupement alkyle, alkoxy, hydroxy, alkylthio, mercapto, cyano, amino, nitro, carboxy, alkoxycarbonyle, aminocarbonyle ou carbamoyle, ou bien R1, R 2, R3 et R4 pris deux à deux, forment ensemble avec les atomes de carbone auxquels ils sont reliés, un cycle phényle ou un hétérocycle aromatique de 5 à 7 chaînons; L1 et L2 représentent chacun un atome d'hydrogène ou forment ensemble un groupement -CH2-CH2-; X1, relié à la position 2 ou 3 du cycle aromatique, représente une liaison et dans ce ca s X2 représente un atome d'hydrogène ou d'halogène, ou un groupement alkyle, alkoxy, hydroxy , nitro, cyano ou amino, ou bien X1 et X2 forment ensemble avec deux carbones adjacen ts auxquels ils sont reliés en position 2, 3 ou 4 du cycle aromatique, un groupement cycloalkyle en C4-C7; X3 représente un atome d'hydrogène ou d'halogène, ou u n groupement alkyle, alkoxy, hydroxy, nitro, cyano ou amino; G représente un groupement: (voir formules G1, G2, G3 ou G4) dans lesquels les pointillés indiquent la présence optionnelle d'une double liaison; Alk représente un groupement alkylène en C1-C6, étant entendu que lorsque G1 ou G2contiennent un groupement imidazoline, le groupement Alk- est relié à la position 2 du cycle; n vaut 0 ou 1; T3 représente un groupement alkyle, aryle, arylalkyle, hétéroaryle, ou -53- hétéroarylalkyle; T4 représente un groupement alkyle, aryle, arylalkyle, hétéroaryle, ou hétéroarylalkyle. L'invention vise également les énantiomères et diastéréoisomères des composés de formule (I), ainsi que leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable. Les composés selon l'invention sont utiles comme médicaments pour le traitement de la dépression, de l'anxiété, de la libido, des dysfonctionnements sexuels, des troubles du sommeil, de l'abus de drogue et des troubles du comportement impulsif.The invention relates to new compounds corresponding to formula (I): (see formula I) in which R1, R2, R3 and R4 independently represent a hydrogen or halogen atom or an alkyl, alkoxy or hydroxy group , alkylthio, mercapto, cyano, amino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl or carbamoyl, or else R1, R 2, R3 and R4 taken two by two, form together with the carbon atoms to which they are attached, a phenyl ring or an aromatic heterocycle of 5 to 7 members; L1 and L2 each represent a hydrogen atom or together form a group -CH2-CH2-; X1, linked to position 2 or 3 of the aromatic ring, represents a bond and in this case X2 represents a hydrogen or halogen atom, or an alkyl, alkoxy, hydroxy, nitro, cyano or amino group, or else X1 and X2 together form with two adjacent carbons to which they are linked in position 2, 3 or 4 of the aromatic ring, a C4-C7 cycloalkyl group; X3 represents a hydrogen or halogen atom, or an alkyl, alkoxy, hydroxy, nitro, cyano or amino group; G represents a group: (see formulas G1, G2, G3 or G4) in which the dotted lines indicate the optional presence of a double bond; Alk represents a C1-C6 alkylene group, it being understood that when G1 or G2 contain an imidazoline group, the group Alk- is linked to position 2 of the ring; n is 0 or 1; T3 represents an alkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl group; T4 represents an alkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl group. The invention also relates to the enantiomers and diastereoisomers of the compounds of formula (I), as well as their addition salts with a pharmaceutically acceptable acid or base. The compounds according to the invention are useful as medicaments for the treatment of depression, anxiety, libido, sexual dysfunctions, sleep disorders, drug abuse and disorders of impulsive behavior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR00/08378 | 2000-06-29 | ||
| FR0008378A FR2810979B1 (en) | 2000-06-29 | 2000-06-29 | NOVEL DIPHENYLUREA DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2352405A1 true CA2352405A1 (en) | 2001-12-29 |
| CA2352405C CA2352405C (en) | 2006-10-03 |
Family
ID=8851854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002352405A Expired - Fee Related CA2352405C (en) | 2000-06-29 | 2001-06-29 | New diphenylurea derivatives, their preparation process and the pharmaceutical compounds that contain them |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6784183B2 (en) |
| EP (1) | EP1170288B9 (en) |
| JP (1) | JP3933889B2 (en) |
| KR (1) | KR100485018B1 (en) |
| CN (1) | CN1241916C (en) |
| AR (1) | AR033379A1 (en) |
| AT (1) | ATE273283T1 (en) |
| AU (1) | AU780022B2 (en) |
| BR (1) | BR0102607A (en) |
| CA (1) | CA2352405C (en) |
| DE (1) | DE60104776T2 (en) |
| DK (1) | DK1170288T3 (en) |
| EA (1) | EA005128B1 (en) |
| ES (1) | ES2227088T3 (en) |
| FR (1) | FR2810979B1 (en) |
| HK (1) | HK1042698B (en) |
| HU (1) | HUP0102723A3 (en) |
| NO (1) | NO320310B1 (en) |
| NZ (1) | NZ512658A (en) |
| PL (1) | PL348392A1 (en) |
| PT (1) | PT1170288E (en) |
| SI (1) | SI1170288T1 (en) |
| TR (1) | TR200402069T4 (en) |
| ZA (1) | ZA200105394B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10139416A1 (en) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituted aromatic bicycles, process for their preparation and their use as medicaments |
| TW200306783A (en) * | 2002-04-29 | 2003-12-01 | Fmc Corp | Pesticidal heterocycles |
| AU2003297441A1 (en) * | 2002-12-24 | 2004-07-22 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| WO2004073634A2 (en) * | 2003-02-20 | 2004-09-02 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| WO2005012254A1 (en) | 2003-07-22 | 2005-02-10 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto |
| FR2859723B1 (en) * | 2003-09-16 | 2005-10-21 | Servier Lab | NOVEL BENZOINDOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| ATE521589T1 (en) * | 2003-09-25 | 2011-09-15 | Dompe Spa | AMIDINES AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| US7812176B2 (en) * | 2004-03-23 | 2010-10-12 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof |
| SA05260357B1 (en) * | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | 3-phenyle-pyrazole derivatives as modulators of the 5-ht 2a serotonin receptor useful for the treatment of disorders related thereto |
| US20080015223A1 (en) * | 2004-12-03 | 2008-01-17 | Arena Pharmaceuticals, Inc. | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
| WO2006076592A1 (en) | 2005-01-14 | 2006-07-20 | Cgi Pharmaceuticals, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
| CA2594563A1 (en) * | 2005-01-19 | 2006-07-27 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| WO2007024294A2 (en) | 2005-05-03 | 2007-03-01 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| WO2007136680A2 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | 3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| MX349156B (en) | 2006-05-18 | 2017-07-14 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor. |
| ES2536762T3 (en) | 2006-05-18 | 2015-05-28 | Arena Pharmaceuticals, Inc. | Primary amines and their derivatives as 5-HT2A serotonin receptor modulators useful for the treatment of disorders related to this |
| CN100390150C (en) * | 2006-06-05 | 2008-05-28 | 吴汝林 | Method for preparing imidazophenylurea hydrochloride |
| TWI415845B (en) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| MX2009008776A (en) | 2007-02-13 | 2009-08-25 | Schering Corp | Functionally selective alpha2c adrenoreceptor agonists. |
| WO2008100459A1 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| EP2190844B3 (en) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| SI2364142T1 (en) * | 2008-10-28 | 2018-06-29 | Arena Pharmaceuticals, Inc. | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| WO2011075596A1 (en) | 2009-12-18 | 2011-06-23 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| DK2970155T3 (en) * | 2013-03-15 | 2018-08-06 | Bristol Myers Squibb Co | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| MX2017016413A (en) | 2015-06-12 | 2018-08-01 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder. |
| MX2018000465A (en) | 2015-07-15 | 2018-09-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981000543A1 (en) * | 1979-08-23 | 1981-03-05 | Caterpillar Tractor Co | Track assembly anti-torsion chains and method |
| GB9313913D0 (en) * | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
| WO1995006044A1 (en) * | 1993-08-20 | 1995-03-02 | Smithkline Beecham Plc | Amide and urea derivatives as 5ht1d receptor antagonists |
| GB9420999D0 (en) * | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| JP2001508767A (en) * | 1996-12-02 | 2001-07-03 | 藤沢薬品工業株式会社 | Indole-urea derivatives having 5-HT antagonism |
| CA2288172A1 (en) * | 1997-04-18 | 1998-10-29 | Smithkline Beecham P.L.C. | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
-
2000
- 2000-06-29 FR FR0008378A patent/FR2810979B1/en not_active Expired - Fee Related
-
2001
- 2001-06-27 AR ARP010103052A patent/AR033379A1/en active IP Right Grant
- 2001-06-27 KR KR10-2001-0036983A patent/KR100485018B1/en not_active IP Right Cessation
- 2001-06-28 NZ NZ512658A patent/NZ512658A/en unknown
- 2001-06-28 EA EA200100600A patent/EA005128B1/en not_active IP Right Cessation
- 2001-06-28 NO NO20013254A patent/NO320310B1/en not_active IP Right Cessation
- 2001-06-28 JP JP2001195947A patent/JP3933889B2/en not_active Expired - Fee Related
- 2001-06-29 BR BR0102607-0A patent/BR0102607A/en not_active Application Discontinuation
- 2001-06-29 AU AU54144/01A patent/AU780022B2/en not_active Ceased
- 2001-06-29 CA CA002352405A patent/CA2352405C/en not_active Expired - Fee Related
- 2001-06-29 PT PT01401712T patent/PT1170288E/en unknown
- 2001-06-29 SI SI200130180T patent/SI1170288T1/en unknown
- 2001-06-29 EP EP01401712A patent/EP1170288B9/en not_active Expired - Lifetime
- 2001-06-29 PL PL01348392A patent/PL348392A1/en not_active Application Discontinuation
- 2001-06-29 TR TR2004/02069T patent/TR200402069T4/en unknown
- 2001-06-29 DK DK01401712T patent/DK1170288T3/en active
- 2001-06-29 US US09/896,278 patent/US6784183B2/en not_active Expired - Fee Related
- 2001-06-29 HU HU0102723A patent/HUP0102723A3/en unknown
- 2001-06-29 DE DE60104776T patent/DE60104776T2/en not_active Expired - Lifetime
- 2001-06-29 ZA ZA200105394A patent/ZA200105394B/en unknown
- 2001-06-29 ES ES01401712T patent/ES2227088T3/en not_active Expired - Lifetime
- 2001-06-29 AT AT01401712T patent/ATE273283T1/en not_active IP Right Cessation
- 2001-06-29 CN CNB011232757A patent/CN1241916C/en not_active Expired - Fee Related
-
2002
- 2002-05-31 HK HK02104086.5A patent/HK1042698B/en not_active IP Right Cessation
-
2004
- 2004-06-07 US US10/862,546 patent/US7026357B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2352405A1 (en) | New diphenylurea derivatives, their preparation process and the pharmaceutical compounds that contain them | |
| MA27596A1 (en) | BENZOCONDENSED HETEROARYLAMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR THEIR USE | |
| MA27568A1 (en) | PYRROLOPYRIMIDINE DERIVATIVES | |
| EA200870384A1 (en) | 3,7-DIAMINO-10H-PHENOTIAZINE SALTS AND THEIR APPLICATION | |
| MA30231B1 (en) | BENZAMIDE AND HETEROARENE DERIVATIVES | |
| MA27569A1 (en) | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | |
| MA26952A1 (en) | IMIDAZOLE DERIVATIVES WITH CONDENSED ARYLATED OR HETEROARYL CORES, USEFUL AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. | |
| ATE253546T1 (en) | CHALCONIC DERIVATIVES AND MEDICATIONS THAT CONTAIN THEM | |
| DK0976748T3 (en) | Pyrrolidine derivatives with phospholipase A2 inhibitory activity | |
| MX19368A (en) | PROCEDURE FOR THE PREPARATION OF HETERO-CYCLIC DERIVATIVES CONTAINING BENZOFUSED NITROGEN AND COMPOUND OBTAINED. | |
| EP1642880A4 (en) | Hsp90 family protein inhibitors | |
| MA33128B1 (en) | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF P38 MAP KINASE | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| DE602004031722D1 (en) | CONDENSED BICYCLIC SUBSTITUTED AMINE AS HISTAMIN 3 RECEPTOR LIGANDS | |
| MA27593A1 (en) | N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FOOD DISORDERS. | |
| CA2323720A1 (en) | New substances derived from aza-indolic polycyclics, processes for preparing them and pharmaceutical compounds containing them | |
| ATE412628T1 (en) | N-(1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES | |
| CA2364864A1 (en) | New metalloprotease inhibitors, the procedure for preparing them and the pharmaceutical compounds containing them | |
| CY1110622T1 (en) | NEW PRODUCTS OF 3-PHENYLOPROPIONIC ACID FOR TREATMENT OF DIABETES | |
| WO2001044207B1 (en) | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them | |
| CA2326710A1 (en) | New dihydrofuro-¬3,4-b|quinolein-1-ones derivatives, the procedure for preparing them and the pharmaceutical compositions that contain them | |
| CA2297279A1 (en) | New cyano-indole compounds that inhibit serotonin recapture, the process for their preparation and the pharmaceutical compounds that contain them | |
| DE69812028D1 (en) | Creatine derivatives for asthma | |
| CA2323703A1 (en) | New cyano-indole serotonin reuptake inhibitors, the procedure for preparing them and the pharmaceutical formulations that contain them | |
| CA2354123A1 (en) | New benzothiadiazine derivatives, their preparation process and the pharmaceutical compositions that contain them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |